New molecule developed at Vanderbilt could be game changer in fight against Alzheimer's
A new study of all cause death in the 12 months following the first incidence of psychosis found a much higher than anticipated death rate in those ages 16-30.
After a decade of work, Vanderbilt scientists have received the green light to take a novel drug to the next step in humans.
You may not be getting all you can out of your browsing experience
and may be open to security risks!
Consider upgrading to the latest version of your browser or choose on below: